サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1462605

がん支持療法薬の2030年までの市場予測：がんタイプ、支持療法タイプ、薬剤タイプ、投与方法、流通チャネル、地域別の世界分析

Cancer Supportive Care Drugs Market Forecasts to 2030 - Global Analysis By Cancer Type, Supportive Care Type, Drug Type, Mode of Administration, Distribution Channel and By Geography

出版日
ページ情報
英文 200+ Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
がん支持療法薬の2030年までの市場予測：がんタイプ、支持療法タイプ、薬剤タイプ、投与方法、流通チャネル、地域別の世界分析
出版日: 2024年04月04日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界のがん支持療法薬市場は2023年に214億6,000万米ドルを占め、2030年には265億7,000万米ドルに達すると予測され、予測期間中のCAGRは2.4%です。

がん支持療法薬は、がん治療の症状や副作用を管理するために設計された薬剤であり、患者のQOL向上を目指しています。これらの薬剤は、化学療法、放射線療法、その他のがん治療によって引き起こされる痛み、吐き気、疲労、免疫抑制などのさまざまな問題を対象としています。これらの薬剤には鎮痛剤、制吐剤、造血成長因子、抗炎症剤などが含まれます。これらの薬剤はまた、不快感を軽減し、全体的な幸福感を高めることで、治療のアドヒアランスを維持するのに役立ちます。

米国国立がん研究所のSEERデータベースによると、2020年、今後20年間で新たに発生するがんの数は2,840万人になると予想されています。

世界的に増加するがんの有病率

がんと診断される人の増加に伴い、がん治療に伴う症状や副作用を管理するための支持療法薬の需要が高まっています。このような需要の増加は、痛み、吐き気、疲労、その他の治療に関連する合併症を緩和し、患者の生活の質を高める必要性から生じています。その結果、製薬会社は支持療法薬の開発と技術革新に意欲を燃やし、世界中のがん患者の高まる医療ニーズに応えるべく市場開拓を推進しています。

副作用と毒性

がん支持療法薬の副作用には、吐き気、嘔吐、疲労、貧血、神経障害、免疫抑制などがあります。さらに、薬剤によっては肝臓や腎臓などの臓器に毒性を示す危険性があります。このような副作用や毒性は、治療の中断、減量、中止を招き、患者のアドヒアランスや治療成績に影響を及ぼします。さらに、副作用に対する懸念が医療従事者の特定の薬剤の処方を躊躇させ、市場の需要に影響を与える可能性もあります。

緩和ケアサービスの拡大

緩和ケアの統合により、疼痛、吐き気、その他の副作用を管理することの重要性が強調され、支持療法薬の開発と採用が促されています。緩和ケアサービスの拡大は、がん患者の症状を緩和しQOLを改善する薬剤の需要を増大させる。このような拡大は患者の幸福を高めるだけでなく、製薬企業ががん治療を受けている患者特有のニーズに対応した新しい治療法を革新・導入しやすい環境を作り出し、市場の成長に拍車をかけています。

不十分なヘルスケアインフラ

不十分な施設、訓練を受けた人材、資源は、診断、治療開始、がんに関連する症状の適切な管理の遅れにつながります。さらに、インフラの不備はしばしば医療提供に格差をもたらし、十分なサービスを受けていない人々に不釣り合いな影響を及ぼします。包括的ながん治療を支える十分なインフラがなければ、支持療法薬の需要は満たされないままであり、市場の拡大を妨げ、症状を緩和し生活の質を改善するために不可欠な治療を患者から奪っています。

COVID-19の影響

COVID-19の流行は、がん支持療法薬市場に大きな影響を与えています。がん検診、診断、治療の遅れとヘルスケアサービスの混乱が、支持療法薬の需要に影響を及ぼしています。さらに、パンデミックに対処するためのサプライチェーンの混乱とリソースの再配分が、市場のダイナミクスをさらに緊張させています。全体として、パンデミックはレジリエントなヘルスケアシステムの重要性を強調し、がん治療の提供における革新的なアプローチの必要性を浮き彫りにしました。

予測期間中、前立腺がん分野が最大となる見込み

前立腺がん分野は、有利な成長を遂げると推定されます。がん支持療法薬の領域では、前立腺がんの課題への対処には多面的なアプローチが必要です。前立腺がんの支持療法薬は、治療の副作用を軽減し、患者のQOLを改善することを目的としています。さらに、排尿障害や勃起障害など、前立腺がん特有の症状や合併症を標的とした薬剤も重要な役割を果たす可能性があります。これらの薬剤の開発と入手可能性は、前立腺がん患者の全人的ケアと幸福を高める上で極めて重要です。

予測期間中にCAGRが最も高くなると予想されるのは静脈注射薬セグメントです。

静脈注射薬セグメントは、予測期間中に最も高いCAGRの成長が見込まれます。静脈注射薬は、薬物を血流に直接送り込み、迅速かつ効率的な吸収を確保することで、がん支持療法において極めて重要な役割を果たしています。これらの薬剤は、吐き気、嘔吐、貧血、好中球減少、疼痛などの化学療法による副作用の管理に極めて重要です。これらの薬剤は標的を絞った治療を提供するため、正確な投与と即時の緩和が可能となり、治療中のがん患者の生活の質を向上させる。

最大のシェアを占める地域

予測期間中、アジア太平洋地域が最大の市場シェアを占めると予測されます。特に中国やインドのような人口の多い国でがん罹患率が増加しており、がん治療の症状や副作用を管理するための支持療法薬の需要が高まっています。さらに、ヘルスケアインフラの改善やがん治療に対する意識の高まりも市場拡大に寄与しています。さらに、製薬企業とヘルスケア機関の協力関係や、がんケアサービスを強化するための政府の取り組みが、がん支持療法薬市場の成長をさらに後押ししています。

CAGRが最も高い地域：

予測期間中、北米のCAGRが最も高いと予測されます。がん罹患率の高さ、高度なヘルスケアインフラ、研究開発の重視といった要因が、この成長に寄与しています。さらに、好意的な償還政策や患者・医療従事者双方の意識の高まりが、支持療法薬の需要を後押ししています。患者の転帰とQOLの向上に重点を置く北米は、がん支持療法薬の開発と商業化にとって依然として重要な地域です。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査資料
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • 新興市場
  • COVID-19症の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界のがん支持療法薬市場：がんタイプ別

  • 乳がん
  • 肺がん
  • 前立腺がん
  • 大腸がん
  • その他のがんタイプ

第6章 世界のがん支持療法薬市場：支持療法タイプ別

  • 化学療法誘発性悪心・嘔吐（CINV）の管理
  • 貧血管理
  • 好中球減少症の管理
  • 骨転移の管理
  • 疼痛管理
  • 疲労管理
  • その他の支持療法タイプ

第7章 世界のがん支持療法薬市場：薬剤タイプ別

  • 制吐剤
  • 赤血球生成刺激因子（ESA）
  • 顆粒球コロニー刺激因子（G-CSF）
  • ビスフォスフォネート
  • 非ステロイド性抗炎症薬（NSAID）
  • コルチコステロイド
  • その他の薬剤タイプ

第8章 世界のがん支持療法薬市場：投与方法別

  • 経口薬
  • 注射薬
  • 外用薬
  • 静脈内投与薬
  • その他の管理方法

第9章 世界のがん支持療法薬市場：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • がん治療センター
  • その他の流通チャネル

第10章 世界のがん支持療法薬市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第11章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品発売
  • 事業拡大
  • その他の主要戦略

第12章 企業プロファイリング

  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Limited
  • F. Hoffmann-La Roche Limited
  • Bayer AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Daiichi Sankyo Company
図表

List of Tables

  • Table 1 Global Cancer Supportive Care Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Cancer Supportive Care Drugs Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 4 Global Cancer Supportive Care Drugs Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 5 Global Cancer Supportive Care Drugs Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 6 Global Cancer Supportive Care Drugs Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 7 Global Cancer Supportive Care Drugs Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 8 Global Cancer Supportive Care Drugs Market Outlook, By Supportive Care Type (2021-2030) ($MN)
  • Table 9 Global Cancer Supportive Care Drugs Market Outlook, By Chemotherapy-induced Nausea & Vomiting (CINV) Management (2021-2030) ($MN)
  • Table 10 Global Cancer Supportive Care Drugs Market Outlook, By Anaemia Management (2021-2030) ($MN)
  • Table 11 Global Cancer Supportive Care Drugs Market Outlook, By Neutropenia Management (2021-2030) ($MN)
  • Table 12 Global Cancer Supportive Care Drugs Market Outlook, By Bone Metastasis Management (2021-2030) ($MN)
  • Table 13 Global Cancer Supportive Care Drugs Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 14 Global Cancer Supportive Care Drugs Market Outlook, By Fatigue Management (2021-2030) ($MN)
  • Table 15 Global Cancer Supportive Care Drugs Market Outlook, By Other Supportive Care Types (2021-2030) ($MN)
  • Table 16 Global Cancer Supportive Care Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 17 Global Cancer Supportive Care Drugs Market Outlook, By Anti-emetics (2021-2030) ($MN)
  • Table 18 Global Cancer Supportive Care Drugs Market Outlook, By Erythropoiesis-stimulating Agents (ESAs) (2021-2030) ($MN)
  • Table 19 Global Cancer Supportive Care Drugs Market Outlook, By Granulocyte Colony-stimulating Factors (G-CSFs) (2021-2030) ($MN)
  • Table 20 Global Cancer Supportive Care Drugs Market Outlook, By Bisphosphonates (2021-2030) ($MN)
  • Table 21 Global Cancer Supportive Care Drugs Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 22 Global Cancer Supportive Care Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 23 Global Cancer Supportive Care Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 24 Global Cancer Supportive Care Drugs Market Outlook, By Mode of Administration (2021-2030) ($MN)
  • Table 25 Global Cancer Supportive Care Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
  • Table 26 Global Cancer Supportive Care Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
  • Table 27 Global Cancer Supportive Care Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
  • Table 28 Global Cancer Supportive Care Drugs Market Outlook, By Intravenous Drugs (2021-2030) ($MN)
  • Table 29 Global Cancer Supportive Care Drugs Market Outlook, By Other Mode of Administrations (2021-2030) ($MN)
  • Table 30 Global Cancer Supportive Care Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Cancer Supportive Care Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 Global Cancer Supportive Care Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 Global Cancer Supportive Care Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Cancer Supportive Care Drugs Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 35 Global Cancer Supportive Care Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC25656

According to Stratistics MRC, the Global Cancer Supportive Care Drugs Market is accounted for $21.46 billion in 2023 and is expected to reach $26.57 billion by 2030 growing at a CAGR of 2.4% during the forecast period. Cancer supportive care drugs are medications designed to manage the symptoms and side effects of cancer treatment, aiming to improve patients' quality of life. These drugs target various issues such as pain, nausea, fatigue, and immune suppression caused by chemotherapy, radiation therapy, or other cancer treatments. They include analgesics, antiemetics, hematopoietic growth factors, and anti-inflammatory agents. These drugs also assist in maintaining treatment adherence by reducing discomfort and enhancing overall well-being.

According to the SEER Database of the U.S. National Cancer Institute, 2020, in the next twenty years, there will likely be 28.4 million new instances of cancer.

Market Dynamics:

Driver:

Rising prevalence of cancer globally

With an increasing number of individuals diagnosed with cancer, there is a higher demand for supportive care drugs to manage symptoms and side effects associated with cancer treatments. This increased demand stems from the necessity to alleviate pain, nausea, fatigue, and other treatment-related complications, enhancing patients' quality of life. Consequently, pharmaceutical companies are motivated to develop and innovate supportive care drugs, driving market expansion to meet the growing healthcare needs of cancer patients worldwide.

Restraint:

Side effects and toxicity

Side effects of cancer supportive care drugs can include nausea, vomiting, fatigue, anaemia, neuropathy, and immunosuppression. Additionally, some drugs may pose risks of toxicity to organs such as the liver or kidneys. These side effects and toxicities can lead to treatment interruptions, dose reductions, or discontinuation, affecting patient adherence and treatment outcomes. Moreover, concerns about adverse effects may deter healthcare providers from prescribing certain drugs, impacting market demand.

Opportunity:

Expansion of palliative care services

Palliative care integration underscores the importance of managing pain, nausea, and other side effects, prompting the development and adoption of supportive care drugs. Expansion of palliative care services increases the demand for medications that alleviate symptoms and improve quality of life for cancer patients. This expansion not only enhances patient well-being but also creates a conducive environment for pharmaceutical companies to innovate and introduce new therapies tailored to address the unique needs of individuals undergoing cancer treatment, thereby fueling market growth.

Threat:

Inadequate healthcare infrastructure

Insufficient facilities, trained personnel, and resources lead to delays in diagnosis, treatment initiation, and proper management of cancer-related symptoms. Moreover, poor infrastructure often results in disparities in healthcare delivery, disproportionately affecting underserved populations. Without adequate infrastructure to support comprehensive cancer care, the demand for supportive care drugs remains unmet, hindering market expansion and depriving patients of essential treatments to alleviate symptoms and improve quality of life.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the cancer supportive care drugs market. Delays in cancer screenings, diagnosis, and treatment, alongside disruptions in healthcare services, have affected the demand for supportive care drugs. Additionally, supply chain disruptions and resource reallocation to address the pandemic have further strained market dynamics. Overall, the pandemic has underscored the importance of resilient healthcare systems and highlighted the need for innovative approaches to cancer care delivery.

The prostate cancer segment is expected to be the largest during the forecast period

The prostate cancer segment is estimated to have a lucrative growth. In the realm of cancer supportive care drugs, addressing the challenges of prostate cancer entails a multifaceted approach. Supportive care drugs for prostate cancer aim to mitigate treatment side effects and improve patients' quality of life. Additionally, drugs targeting prostate cancer-specific symptoms and complications, such as urinary issues or erectile dysfunction, may also play a crucial role. The development and availability of these drugs are pivotal in enhancing the holistic care and well-being of prostate cancer patients.

The intravenous drugs segment is expected to have the highest CAGR during the forecast period

The intravenous drugs segment is anticipated to witness the highest CAGR growth during the forecast period. Intravenous drugs play a pivotal role in cancer supportive care by delivering medications directly into the bloodstream, ensuring rapid and efficient absorption. These drugs are crucial for managing chemotherapy-induced side effects such as nausea, vomiting, anaemia, neutropenia, and pain. They offer targeted treatment, allowing for precise dosing and immediate relief, thereby enhancing the quality of life for cancer patients undergoing treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing cancer prevalence, particularly in populous countries like China and India, drives demand for supportive care drugs to manage symptoms and side effects of cancer treatment. Additionally, improving healthcare infrastructure and rising awareness about cancer care contribute to market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with government initiatives to enhance cancer care services, further propel the growth of the cancer supportive care drugs market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and strong emphasis on research and development contribute to this growth. Moreover, favourable reimbursement policies and increasing awareness among both patients and healthcare providers drive demand for supportive care drugs. With a focus on improving patient outcomes and quality of life, North America remains a key region for the development and commercialization of cancer supportive care drugs.

Key players in the market

Some of the key players profiled in the Cancer Supportive Care Drugs Market include Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis International AG, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, F. Hoffmann-La Roche Limited, Bayer AG, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, AbbVie Inc. and Daiichi Sankyo Company.

Key Developments:

In November 2023, AstraZeneca's Truqap in combination with Faslodex has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations. Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

In March 2022, Novartis received approval from the United States Food and Administration (FDA) for Pluvicto, developed for the treatment of adult patients with prostate cancer. The cancer supportive care drug by Novartis is specially designed for cancer patients that already have had other anti-cancer therapies.

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Other Cancer Types

Supportive Care Types Covered:

  • Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • Anaemia Management
  • Neutropenia Management
  • Bone Metastasis Management
  • Pain Management
  • Fatigue Management
  • Other Supportive Care Types

Drug Types Covered:

  • Anti-emetics
  • Erythropoiesis-stimulating Agents (ESAs)
  • Granulocyte Colony-stimulating Factors (G-CSFs)
  • Bisphosphonates
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Other Drug Types

Mode of Administrations Covered:

  • Oral Drugs
  • Injectable Drugs
  • Topical Drugs
  • Intravenous Drugs
  • Other Mode of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Cancer Treatment Centers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Supportive Care Drugs Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Breast Cancer
  • 5.3 Lung Cancer
  • 5.4 Prostate Cancer
  • 5.5 Colorectal Cancer
  • 5.6 Other Cancer Types

6 Global Cancer Supportive Care Drugs Market, By Supportive Care Type

  • 6.1 Introduction
  • 6.2 Chemotherapy-induced Nausea & Vomiting (CINV) Management
  • 6.3 Anaemia Management
  • 6.4 Neutropenia Management
  • 6.5 Bone Metastasis Management
  • 6.6 Pain Management
  • 6.7 Fatigue Management
  • 6.8 Other Supportive Care Types

7 Global Cancer Supportive Care Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Anti-emetics
  • 7.3 Erythropoiesis-stimulating Agents (ESAs)
  • 7.4 Granulocyte Colony-stimulating Factors (G-CSFs)
  • 7.5 Bisphosphonates
  • 7.6 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.7 Corticosteroids
  • 7.8 Other Drug Types

8 Global Cancer Supportive Care Drugs Market, By Mode of Administration

  • 8.1 Introduction
  • 8.2 Oral Drugs
  • 8.3 Injectable Drugs
  • 8.4 Topical Drugs
  • 8.5 Intravenous Drugs
  • 8.6 Other Mode of Administrations

9 Global Cancer Supportive Care Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Cancer Treatment Centers
  • 9.6 Other Distribution Channels

10 Global Cancer Supportive Care Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 Johnson & Johnson
  • 12.3 Pfizer Inc.
  • 12.4 Novartis International AG
  • 12.5 Merck & Co. Inc.
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 F. Hoffmann-La Roche Limited
  • 12.8 Bayer AG
  • 12.9 Eli Lilly and Company
  • 12.10 AstraZeneca PLC
  • 12.11 Bristol Myers Squibb
  • 12.12 GlaxoSmithKline PLC
  • 12.13 Takeda Pharmaceutical Company Limited
  • 12.14 AbbVie Inc.
  • 12.15 Daiichi Sankyo Company